Literature DB >> 2179409

Immunologic and physicochemical evidence for conformational changes occurring on conversion of human mast cell tryptase from active tetramer to inactive monomer. Production of monoclonal antibodies recognizing active tryptase.

L B Schwartz1, T R Bradford, D C Lee, J F Chlebowski.   

Abstract

The catalytic activity of human tryptase, a mast cell neutral endoprotease, is expressed when the enzyme is in its tetrameric form, but is lost under physiologic conditions concomitant with a quaternary structural alteration involving conversion to a monomeric form. The associated changes in the CD spectra noted in the current study indicate accompanying alterations in the secondary structure of the protein. In particular, the progressive disappearance of the negative minimum centered at 228 nm suggests an effect on beta-sheet structure, which may be important for monomer-monomer interaction and/or stabilization of catalytic activity. Dextran sulfate, like heparin, stabilizes the catalytic activity and quaternary structure of tryptase and also maintains the native secondary structure of the enzyme at and beyond a temperature of 40 degrees C. Dextran sulfate-stabilized tryptase therefore was used as an immunogen to which were produced three murine mAb (B2, C11, and G4) recognizing the catalytically active form of the enzyme. Inactive tryptase bound to plastic microtiter wells was not recognized by any of the newly made antibodies, whereas inactive tryptase in solution was recognized by G4, which when biotinylated, could be used as a detector antibody in a sandwich ELISA for tryptase. Each of the newly made mAb recognized the catalytically active form of tryptase. Thus, alterations in epitopes, perhaps reflecting tertiary structural alterations as well as changes in secondary and quaternary conformations, occur with tryptase inactivation. A pragmatic result of these newly generated antibodies is the affinity purification to homogeneity of active tryptase by sequential chromatography with B2 coupled to CH-Sepharose and heparin-agarose. Tryptase purified by this technique had a specific activity with p-tosyl-L-arginine methyl ester of 117 +/- 9 U/mg and had 3.9 +/- 0.3 active sites per molecule of active enzyme (134,000 m.w.) as titrated with p-nitrophenyl-p'-guanidinobenzoate. The spectral and immunologic data in the current study are consistent with concerted conformational alterations in the secondary and tertiary as well as quaternary structures of tryptase associated with loss of catalytic activity. Failure to reverse any of these alterations with dextran sulfate suggests that the pathway of tetramer assembly in vivo is more complicated than simple subunit association.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2179409

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized beta-tryptase to form monomers that are inactive at neutral pH and active at acidic pH.

Authors:  Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

2.  Promiscuous processing of human alphabeta-protryptases by cathepsins L, B, and C.

Authors:  Quang T Le; Hae-Ki Min; Han-Zhang Xia; Yoshihiro Fukuoka; Nobuhiko Katunuma; Lawrence B Schwartz
Journal:  J Immunol       Date:  2011-05-11       Impact factor: 5.422

3.  A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I.

Authors:  K Sakai; S Ren; L B Schwartz
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

4.  Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis.

Authors:  L B Schwartz; T R Bradford; C Rouse; A M Irani; G Rasp; J K Van der Zwan; P W Van der Linden
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

5.  Dual functionality of β-tryptase protomers as both proteases and cofactors in the active tetramer.

Authors:  Henry R Maun; Peter S Liu; Yvonne Franke; Charles Eigenbrot; William F Forrest; Lawrence B Schwartz; Robert A Lazarus
Journal:  J Biol Chem       Date:  2018-04-16       Impact factor: 5.157

6.  The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis.

Authors:  L B Schwartz; K Sakai; T R Bradford; S Ren; B Zweiman; A S Worobec; D D Metcalfe
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

7.  Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5.

Authors:  Yoshihiro Fukuoka; Han-Zhang Xia; Laura B Sanchez-Muñoz; Anthony L Dellinger; Luis Escribano; Lawrence B Schwartz
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

Review 8.  Active monomers of human beta-tryptase have expanded substrate specificities.

Authors:  Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  Int Immunopharmacol       Date:  2007-07-27       Impact factor: 4.932

9.  Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelope glycoprotein.

Authors:  I T Harvima; R J Harvima; G Nilsson; L Ivanoff; L B Schwartz
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

10.  Evaluation of mast cell activation (tryptase) in two patients suffering from drug-induced hypotensoid reactions.

Authors:  P Matsson; I Enander; A S Andersson; J Nystrand; L Schwartz; J Watkins
Journal:  Agents Actions       Date:  1991-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.